Index
Grant: Eiger InnoTherapeutics — Lonafarnib and Pegylated Interferon Lambda (Coefficient Giving → Eiger InnoTherapeutics)
Verdictconfirmed95%
1 check · 4/9/2026Deterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Our claim
entire record- Name
- Eiger InnoTherapeutics — Lonafarnib and Pegylated Interferon Lambda
- Amount
- $3,000,000
- Currency
- USD
- Date
- April 2024
- Notes
[Scientific Research] Open Philanthropy recommended an investment of $3,000,000 in Eiger InnoTherapeutics, a new company founded by Professor Jeffrey S. Glenn, that has acquired the rights to two drugs, lonafarnib and pegylated interferon lambda. The company will develop Lonafarn… expand
[Scientific Research] Open Philanthropy recommended an investment of $3,000,000 in Eiger InnoTherapeutics, a new company founded by Professor Jeffrey S. Glenn, that has acquired the rights to two drugs, lonafarnib and pegylated interferon lambda. The company will develop Lonafarnib for use against hepatitis D, for which there is no FDA-approved drug for HDV, the worst form of human viral hepatitis. Interferon Lambda has demonstrated broad-spectrum antiviral activity. The company will seek to work in collaboration with the FDA and other regulatory authorities to address multiple important high unmet needs using interferon lambda. This investment was funded via our request for proposals through the Pandemic Antiviral Discovery Initiative. This falls within our focus area of scientific research.
Source evidence
1 src · 1 checkconfirmed95%deterministic-row-match · 4/9/2026
- Name
- Eiger InnoTherapeutics — Lonafarnib and Pegylated Interferon Lambda
- Grantee
- Eiger InnoTherapeutics
- Focus Area
- Scientific Research
- Amount
- $3,000,000.00
- Date
- April 2024
NoteDeterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Case № Z8dWZHr-BZFiled 4/9/2026Confidence 95%